The role of TET family proteins and 5-hydroxymethylcytosine in human tumors

Histology and Histopathology

Volumn 29, Issue 8, 2014, Pages 991-997

  Wu, Yi Chen ^a   Ling, Zhi Qiang ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

5 hmC; IDH; TET family proteins; Tumor; KG

Indexed keywords

5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA BINDING PROTEIN;

ANALOGS AND DERIVATIVES; CELL TRANSFORMATION; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY;

CELL TRANSFORMATION, NEOPLASTIC; CYTOSINE; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 84904103942     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., Heguy A., Bueso-Ramos C., Kantarjian H., Levine R. L. and Verstovsek S. (2010). Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 70, 447-452.
2. Burmeister T., Meyer C., Schwartz S., Hofmann J., Molkentin M., Kowarz E., Schneider B., Raff T., Reinhardt R., Gokbuget N., Hoelzer D., Thiel E. and Marschalek R. (2009). The ml l recombinome of adult cd10-negative b-cell precursor acute lymphoblastic leukemia: Results from the gmall study group. Blood 113, 4011-4015.
3. Chen M. L., Shen F., Huang W., Qi J. H., Wang Y., Feng Y. Q., Liu S. M. and Yuan B. F. (2013). Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole tof mass spectrometry. Clin. Chem. 59, 824-832.
4. Chou W. C., Chou S. C., Liu C. Y., Chen C. Y., Hou H. A., Kuo Y. Y., Lee M. C., Ko B. S., Tang J. L., Yao M., Tsay W., Wu S. J., Huang S. Y., Hsu S. C., Chen Y. C., Chang Y. C., Kuo Y. Y., Kuo K. T., Lee F. Y., Liu M. C., Liu C. W., Tseng M. H., Huang C. F. and Tien H. F. (2011). Tet2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118, 3803-3810.
5. Dawlaty M. M., Breiling A., Le T., Raddatz G., Barrasa M. I., Cheng A. W., Gao Q., Powell B. E., Li Z., Xu M., Faull K. F., Lyko F. and Jaenisch R. (2013). Combined deficiency of tet1 and tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev. Cell 24, 310-323.
6. Gaidzik V. I., Paschka P., Spath D., Habdank M., Kohne C. H., Germing U., von Lilienfeld-Toal M., Held G., Horst H. A., Haase D., Bentz M., Gotze K., Dohner H., Schlenk R. F., Bullinger L. and Dohner K. (2012). Tet2 mutations in acute myeloid leukemia (aml): Results from a comprehensive genetic and clinical analysis of the aml study group. J. Clin. Pathol. 30, 1350-1357.
7. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., Lagarde A., Prebet T., Nezri M., Sainty D., Olschwang S., Xerri L., Chaffanet M., Mozziconacci M. J., Vey N. and Birnbaum D. (2009). Mutations of polycomb-associated gene asxl1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145, 788-800.
8. Guo J. U., Su Y., Zhong C., Ming G. L. and Song H. (2011). Hydroxylation of 5-methylcytosine by tet1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434.
9. Haffner M. C., Chaux A., Meeker A. K., Esopi D. M., Gerber J., Pellakuru L. G., Toubaji A., Argani P., Iacobuzio-Donahue C., Nelson W. G., Netto G. J., De Marzo A. M. and Yegnasubramanian S. (2011). Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2, 627-637.
10. He Y. F., Li B. Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., Sun Y., Li X., Dai Q., Song C. X., Zhang K., He C. and Xu G. L. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by tdg in mammalian DNA. Science 333, 1303-1307.
11. Inoue A. and Zhang Y. (2011). Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 334, 194.
12. Ito S., Shen L., Dai Q., Wu S. C., Collins L. B., Swenberg J. A., He C. and Zhang Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303.
13. Itzykson R., Kosmider O., Cluzeau T., Mansat-De Mas V., Dreyfus F., Beyne-Rauzy O., Quesnel B., Vey N., Gelsi-Boyer V., Raynaud S., Preudhomme C., Ades L., Fenaux P., Fontenay M. and Groupe Francophone des M. (2011). Impact of tet2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25, 1147-1152.
14. Jin S. G., Jiang Y., Qiu R., Rauch T. A., Wang Y., Schackert G., Krex D., Lu Q. and Pfeifer G. P. (2011). 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with idhl mutations. Cancer Res. 71, 7360-7365.
15. Ko M., Huang Y., Jankowska A. M., Pape U. J., Tahiliani M., Bandukwala H. S., An J., Lamperti E. D., Koh K. P., Ganetzky R., Liu X. S., Aravind L., Agarwal S., Maciejewski J. P. and Rao A. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant tet2. Nature 468, 839-843.
16. Ko M., An J., Bandukwala H. S., Chavez L., Aijo T., Pastor W. A., Segal M. F., Li H., Koh K. P., Lahdesmaki H., Hogan P. G., Aravind L. and Rao A. (2013). Modulation of tet2 expression and 5-methylcytosine oxidation by the cxxc domain protein idax. Nature 497, 122-126.
17. Kraus T. F., Globisch D., Wagner M., Eigenbrod S., Widmann D., Munzel M., Muller M., Pfaffeneder T., Hackner B., Feiden W., Schuller U., Carell T. and Kretzschmar H. A. (2012). Low values of 5-hydroxymethylcytosine (5hmc), the "sixth base, " are associated with anaplasia in human brain tumors. Int. J. Cancer 131, 1577-1590.
18. Kudo Y., Tateishi K., Yamamoto K., Yamamoto S., Asaoka Y., Ijichi H., Nagae G., Yoshida H., Aburatani H. and Koike K. (2012). Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103, 670-676.
19. Langemeijer S. M., Kuiper R. P., Berends M., Knops R., Aslanyan M. G., Massop M., Stevens-Linders E., van Hoogen P., van Kessel A. G., Raymakers R. A., Kamping E. J., Verhoef G. E., Verburgh E., Hagemeijer A., Vandenberghe P., de Witte T., van der Reijden B. A. and Jansen J. H. (2009). Acquired mutations in tet2 are common in myelodysplastic syndromes. Nature Genet. 41, 838-842.
20. Lian C. G., Xu Y., Ceol C., Wu F., Larson A., Dresser K., Xu W., Tan L., Hu Y., Zhan Q., Lee C. W., Hu D., Lian B. Q., Kleffel S., Yang Y., Neiswender J., Khorasani A. J., Fang R., Lezcano C., Duncan L. M., Scolyer R. A., Thompson J. F., Kakavand H., Houvras Y., Zon L. I., Mihm M. C. Jr, Kaiser U. B., Schatton T., Woda B. A., Murphy G. F. and Shi Y. G. (2012). Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135-1146.
21. Mohr F., Dohner K., Buske C. and Rawat V. P. (2011). Tet genes: New players in DNA demethylation and important determinants for stemness. Exp. Hematol. 39, 272-281.
22. Orr B. A., Haffner M. C., Nelson W. G., Yegnasubramanian S. and Eberhart C. G. (2012). Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PloS one 7, e41036.
23. Parsons D. W., Jones S., Zhang X., Lin J. C., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I. M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A. Jr, Hartigan J., Smith D. R., Strausberg R. L., Marie S. K., Shinjo S. M., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E. and Kinzler K. W. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
24. Patel J. P., Gonen M., Figueroa M. E., Fernandez H., Sun Z., Racevskis J., Van Vlierberghe P., Dolgalev I., Thomas S., Aminova O., Huberman K., Cheng J., Viale A., Socci N. D., Heguy A., Cherry A., Vance G., Higgins R. R., Ketterling R. P., Gallagher R. E., Litzow M., van den Brink M. R., Lazarus H. M., Rowe J. M., Luger S., Ferrando A., Paietta E., Tallman M. S., Melnick A., Abdel-Wahab O. and Levine R. L. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England J. Med. 366, 1079-1089.
25. Schaub F. X., Looser R., Li S., Hao-Shen H., Lehmann T., Tichelli A. and Skoda R. C. (2010). Clonal analysis of tet2 and jak2 mutations suggests that tet2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115, 2003-2007.
26. Tahiliani M., Koh K. P., Shen Y., Pastor W. A., Bandukwala H., Brudno Y., Agarwal S., Iyer L. M., Liu D. R., Aravind L. and Rao A. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by mll partner tet1. Science 324, 930-935.
27. Tan L. and Shi Y. G. (2012). Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 139, 1895-1902.
28. Upadhyay A. K., Horton J. R., Zhang X. and Cheng X. (2011). Coordinated methyl-lysine erasure: Structural and functional linkage of a jumonji demethylase domain and a reader domain. Curr. Opin. Struct. Biol. 21, 750-760.
29. Valinluck V. and Sowers L. C. (2007). Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase dnmt1. Cancer Res. 67, 946-950.
30. Valinluck V., Tsai H. H., Rogstad D. K., Burdzy A., Bird A. and Sowers L. C. (2004). Oxidative damage to methyl-cpg sequences inhibits the binding of the methyl-cpg binding domain (mbd) of methyl-cpg binding protein 2 (mecp2). Nucleic Acid Res. 32, 4100-4108.
31. Wu S. C. and Zhang Y. (2010). Active DNA demethylation: Many roads lead to rome. Nature reviews. Molecular cell biology 11, 607-620.
32. Wyatt G. R. and Cohen S. S. (1953). The bases of the nucleic acids of some bacterial and animal vi ruses: The occurrence of 5-hydroxymethylcytosine. Biochem. J. 55, 774-782.
33. Xiao M., Yang H., Xu W., Ma S., Lin H., Zhu H., Liu L., Liu Y., Yang C., Xu Y., Zhao S., Ye D., Xiong Y. and Guan K. L. (2012). Inhibition of alpha-kg-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of fh and sdh tumor suppressors. Genes Dev. 26, 1326-1338.
34. Xu Y., Wu F., Tan L., Kong L., Xiong L., Deng J., Barbera A. J., Zheng L., Zhang H., Huang S., Min J., Nicholson T., Chen T., Xu G., Shi Y., Zhang K. and Shi Y. G. (2011). Genome-wide regulation of 5hmc, 5mc, and gene expression by tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 42, 451-464.
35. Yang H., Ye D., Guan K. L. and Xiong Y. (2012). Idh1 and idh2 mutations in tumorigenesis: Mechanistic insights and clinical perspectives. Clin. Cancer Res. 18, 5562-5571.